{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:14:25Z","timestamp":1790644465209,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81800195"],"award-info":[{"award-number":["81800195"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key Clinical Projects of Peking University Third Hospital","award":["BYSYZD2019026"],"award-info":[{"award-number":["BYSYZD2019026"]}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"crossref","award":["Y-NCJH202201-0049"],"award-info":[{"award-number":["Y-NCJH202201-0049"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the special fund of the National Clinical Key Specialty Construction Program, P. R. China (2023)."},{"name":"the\u00a0National\u00a0Clinical\u00a0Key\u00a0Specialty\u00a0Construction\u00a0Program, P. R. China"},{"name":"Beijing Natural Science Foundation","award":["7232202"],"award-info":[{"award-number":["7232202"]}]},{"name":"Beijing Municipal Health Commission, Capital's Funds for Health Improvement and Research","award":["2024-2-4096"],"award-info":[{"award-number":["2024-2-4096"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06771-1","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T02:03:23Z","timestamp":1768961003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma"],"prefix":"10.1007","volume":"105","author":[{"given":"Shuozi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingtong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"12","key":"6771_CR1","doi-asserted-by":"publisher","first-page":"13204","DOI":"10.1002\/cam4.6009","volume":"12","author":"P Yang","year":"2023","unstructured":"Yang P, Cai QQ, Zhang W, Liu SZ, Liu H, Sun XH, Dong YJ, Xiao XB, Wang JW, Li ZL, Huang WR, Li LH, Bao HZ, Yang W, Wang YL, Wang SY, He J, Li XL, Liu AC, Jing HM (2023) Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: a large, multicenter retrospective analysis. Cancer Med 12(12):13204\u201313216. https:\/\/doi.org\/10.1002\/cam4.6009","journal-title":"Cancer Med"},{"issue":"35","key":"6771_CR2","doi-asserted-by":"publisher","first-page":"e12120","DOI":"10.1097\/MD.0000000000012120","volume":"97","author":"J Meng","year":"2018","unstructured":"Meng J, Chang C, Pan H, Zhu F, Xiao Y, Liu T, Nie X, Wu G, Zhang L (2018) Epidemiologic characteristics of malignant lymphoma in Hubei, china: A single-center 5-year retrospective study. Med (Baltim) 97(35):e12120. https:\/\/doi.org\/10.1097\/MD.0000000000012120","journal-title":"Med (Baltim)"},{"issue":"1","key":"6771_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-018-0621-5","volume":"11","author":"S Balaji","year":"2018","unstructured":"Balaji S, Ahmed M, Lorence E, Yan F, Nomie K, Wang M (2018) NF-kappaB signaling and its relevance to the treatment of mantle cell lymphoma. J Hematol Oncol 11(1):83. https:\/\/doi.org\/10.1186\/s13045-018-0621-5","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6771_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13045-018-0556-x","volume":"11","author":"RE Steiner","year":"2018","unstructured":"Steiner RE, Romaguera J, Wang M (2018) Current trials for frontline therapy of mantle cell lymphoma. J Hematol Oncol 11(1):13. https:\/\/doi.org\/10.1186\/s13045-018-0556-x","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6771_CR5","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1038\/s41467-021-22872-z","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, Cai Q, Zhang R, McIntosh J, Wang R, Dang M, Dai E, Wang Y, Santos D, Badillo M, Leeming A, Chen Z, Hartig K, Bigcal J, Wang M (2021) Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun 12(1):2877. https:\/\/doi.org\/10.1038\/s41467-021-22872-z","journal-title":"Nat Commun"},{"issue":"20","key":"6771_CR6","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.21037\/atm-22-4314","volume":"10","author":"S Liu","year":"2022","unstructured":"Liu S, Yang P, Wang L, Li C, Zhang W, Wang J, Jing H (2022) Identification of six hub genes in mantle cell lymphoma patients with BTKi resistance. Ann Transl Med 10(20):1105. https:\/\/doi.org\/10.21037\/atm-22-4314","journal-title":"Ann Transl Med"},{"issue":"14","key":"6771_CR7","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Reagan PM (2020) KTE-X19 CAR t-cell therapy in relapsed or refractory Mantle-Cell lymphoma. N Engl J Med 382(14):1331\u20131342. https:\/\/doi.org\/10.1056\/NEJMoa1914347","journal-title":"N Engl J Med"},{"issue":"5","key":"6771_CR8","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ajh.26523","volume":"97","author":"P Jain","year":"2022","unstructured":"Jain P, Wang ML (2022) Mantle cell lymphoma in 2022-a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol 97(5):638\u2013656. https:\/\/doi.org\/10.1002\/ajh.26523","journal-title":"Am J Hematol"},{"issue":"25","key":"6771_CR9","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1182\/blood.2021012343","volume":"138","author":"O Al-Sawaf","year":"2021","unstructured":"Al-Sawaf O, Fischer K (2021) TP53 mutations in CLL: does frequency matter? Blood 138(25):2600\u20132601. https:\/\/doi.org\/10.1182\/blood.2021012343","journal-title":"Blood"},{"issue":"3","key":"6771_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2021.10.036","volume":"81","author":"KN Maxwell","year":"2022","unstructured":"Maxwell KN, Cheng HH, Powers J, Gulati R, Ledet EM, Morrison C, Le A, Hausler R, Stopfer J, Hyman S, Kohlmann W, Naumer A, Vagher J, Greenberg SE, Naylor L, Laurino M, Konnick EQ, Shirts BH, AlDubayan SH, Pritchard CC (2022) Inherited TP53 variants and risk of prostate cancer. Eur Urol 81(3):243\u2013250. https:\/\/doi.org\/10.1016\/j.eururo.2021.10.036","journal-title":"Eur Urol"},{"issue":"7549","key":"6771_CR11","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nature14418","volume":"520","author":"Y Liu","year":"2015","unstructured":"Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X (2015) TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature 520(7549):697\u2013701. https:\/\/doi.org\/10.1038\/nature14418","journal-title":"Nature"},{"issue":"13","key":"6771_CR12","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","volume":"4","author":"HA Hill","year":"2020","unstructured":"Hill HA, Qi X, Jain P, Nomie K, Wang Y, Zhou S, Wang ML (2020) Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv 4(13):2927\u20132938. https:\/\/doi.org\/10.1182\/bloodadvances.2019001350","journal-title":"Blood Adv"},{"issue":"4","key":"6771_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","volume":"131","author":"SM Aukema","year":"2018","unstructured":"Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-Larue MH, Rymkiewicz G, Thorns C, Hartmann S, Kluin-Nelemans H, Hermine O, Dreyling M, Klapper W (2018) Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL network. Blood 131(4):417\u2013420. https:\/\/doi.org\/10.1182\/blood-2017-07-797019","journal-title":"Blood"},{"key":"6771_CR14","doi-asserted-by":"publisher","unstructured":"Yi S, Yan Y, Jin M, Bhattacharya S, Wang Y, Wu Y, Yang L, Gine E, Clot G, Chen L, Yu Y, Zou D, Wang J, Phan AT, Cui R, Li F, Sun Q, Zhai Q, Wang T, Wang L (2022) Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest 132(3). https:\/\/doi.org\/10.1172\/JCI153283","DOI":"10.1172\/JCI153283"},{"issue":"7","key":"6771_CR15","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, Xiao W (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"issue":"11","key":"6771_CR16","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman AL, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles G, Zelenetz AD (2022) The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood 140(11):1229\u20131253. https:\/\/doi.org\/10.1182\/blood.2022015851","journal-title":"Blood"},{"issue":"11","key":"6771_CR17","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","volume":"21","author":"AD Zelenetz","year":"2023","unstructured":"Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B (2023) NCCN guidelines\u00ae insights: B-cell lymphomas, version 6.2023: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 21(11):1118\u20131131","journal-title":"J Natl Compr Canc Netw"},{"key":"6771_CR18","doi-asserted-by":"publisher","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance AL, Lymphoma G, Oncology EC, Italian Lymphoma G, Hemato-Oncology F, Study G, Study G (2014) A.,. United Kingdom National Cancer Research, I. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol\u00a032(27):3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","DOI":"10.1200\/JCO.2013.54.8800"},{"issue":"3","key":"6771_CR19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3322\/caac.21825","volume":"74","author":"R Casolino","year":"2024","unstructured":"Casolino R, Beer PA, Chakravarty D, Davis MB, Malapelle U, Mazzarella L, Normanno N, Pauli C, Subbiah V, Turnbull C, Westphalen CB, Biankin AV (2024) Interpreting and integrating genomic tests results in clinical cancer care: overview and practical guidance. CA Cancer J Clin 74(3):264\u2013285. https:\/\/doi.org\/10.3322\/caac.21825","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"6771_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN (2017) Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular Pathology, American society of clinical Oncology, and college of American pathologists. J Mol Diagn 19(1):4\u201323. https:\/\/doi.org\/10.1016\/j.jmoldx.2016.10.002","journal-title":"J Mol Diagn"},{"issue":"10","key":"6771_CR21","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","volume":"50","author":"AO Giacomelli","year":"2018","unstructured":"Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, Howard TP, Takeda DY, Ly SH, Kim E, Gannon HS, Hurhula B, Sharpe T, Goodale A, Fritchman B, Steelman S, Vazquez F, Tsherniak A, Aguirre AJ, Hahn WC (2018) Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet 50(10):1381\u20131387. https:\/\/doi.org\/10.1038\/s41588-018-0204-y","journal-title":"Nat Genet"},{"key":"6771_CR22","doi-asserted-by":"publisher","unstructured":"Hsu HC, You JF, Chen SJ, Chen HC, Yeh CY, Tsai WS, Hung HY, Yang TS, Lapke N, Tan KT (2019) TP53 DNA binding domain mutations predict Progression-Free survival of bevacizumab therapy in metastatic colorectal cancer. Cancers (Basel) 11(8). https:\/\/doi.org\/10.3390\/cancers11081079","DOI":"10.3390\/cancers11081079"},{"issue":"690","key":"6771_CR23","doi-asserted-by":"publisher","first-page":"eabn9155","DOI":"10.1126\/scitranslmed.abn9155","volume":"15","author":"H Song","year":"2023","unstructured":"Song H, Wu J, Tang Y, Dai Y, Xiang X, Li Y, Wu L, Wu J, Liang Y, Xing Y, Yan N, Li Y, Wang Z, Xiao S, Li J, Zheng D, Chen X, Fang H, Ye C, Lu M (2023) Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties. Sci Transl Med 15(690):eabn9155. https:\/\/doi.org\/10.1126\/scitranslmed.abn9155","journal-title":"Sci Transl Med"},{"issue":"5","key":"6771_CR24","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41418-022-00976-3","volume":"29","author":"KC de Andra","year":"2022","unstructured":"de Andra KC, Lee EE, Tookmanian EM, Kesserwan CA, Manfredi JJ, Hatton JN, Loukissas JK, Zavadil J, Zhou L, Olivier M, Frone MN, Shahzada O, Longabaugh WJR, Kratz CP, Malkin D, Hainaut P, Savage SA (2022) The TP53 database: transition from the International Agency for Research on Cancer to the US National Cancer Institute. Cell Death Differ 29(5):1071\u20131073. https:\/\/doi.org\/10.1038\/s41418-022-00976-3","journal-title":"Cell Death Differ"},{"issue":"D1","key":"6771_CR25","doi-asserted-by":"publisher","first-page":"D891","DOI":"10.1093\/nar\/gkad1049","volume":"52","author":"PW Harrison","year":"2024","unstructured":"Harrison PW, Amode MR, Austine-Orimoloye O, Azov AG, Barba M, Barnes I, Becker A, Bennett R, Berry A, Bhai J, Bhurji SK, Boddu S, Lins B, Brooks PR, Ramaraju L, Campbell SB, Martinez LI, Charkhchi MC, Chougule M, Yates K, A. D (2024) Ensembl 2024. Nucleic Acids Res 52(D1):D891\u2013D899. https:\/\/doi.org\/10.1093\/nar\/gkad1049","journal-title":"Nucleic Acids Res"},{"issue":"17","key":"6771_CR26","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, Montano-Almendras CP, Husby S, Freiburghaus C, Ek S, Pedersen A, Niemann C, Raty R, Brown P, Geisler CH, Andersen MK, Guldberg P, Jerkeman M, Gronbaek K (2017) TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 130(17):1903\u20131910. https:\/\/doi.org\/10.1182\/blood-2017-04-779736","journal-title":"Blood"},{"key":"6771_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.anndiagpath.2019.05.004","volume":"41","author":"A Sakhdari","year":"2019","unstructured":"Sakhdari A, Ok CY, Patel KP, Kanagal-Shamanna R, Yin CC, Zuo Z, Hu S, Routbort MJ, Luthra R, Medeiros LJ, Khoury JD, Loghavi S (2019) TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol 41:38\u201342. https:\/\/doi.org\/10.1016\/j.anndiagpath.2019.05.004","journal-title":"Ann Diagn Pathol"},{"issue":"2","key":"6771_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.18697","volume":"201","author":"MR Wilson","year":"2023","unstructured":"Wilson MR, Barrett A, Cheah CY, Eyre TA (2023) How i manage mantle cell lymphoma: indolent versus aggressive disease. Br J Haematol 201(2):185\u2013198. https:\/\/doi.org\/10.1111\/bjh.18697","journal-title":"Br J Haematol"},{"issue":"3","key":"6771_CR29","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","volume":"25","author":"PA Muller","year":"2014","unstructured":"Muller PA, Vousden KH (2014) Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25(3):304\u2013317. https:\/\/doi.org\/10.1016\/j.ccr.2014.01.021","journal-title":"Cancer Cell"},{"issue":"16","key":"6771_CR30","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1182\/blood-2011-11-366062","volume":"119","author":"ZY Xu-Monette","year":"2012","unstructured":"Xu-Monette ZY, Medeiros LJ, Li Y, Orlowski RZ, Andreeff M, Bueso-Ramos CE, Greiner TC, McDonnell TJ, Young KH (2012) Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 119(16):3668\u20133683. https:\/\/doi.org\/10.1182\/blood-2011-11-366062","journal-title":"Blood"},{"issue":"3","key":"6771_CR31","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/s1097-2765(03)00050-9","volume":"11","author":"M Mihara","year":"2003","unstructured":"Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM (2003) p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11(3):577\u2013590. https:\/\/doi.org\/10.1016\/s1097-2765(03)00050-9","journal-title":"Mol Cell"},{"issue":"1","key":"6771_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.molcel.2018.06.012","volume":"71","author":"E Kotler","year":"2018","unstructured":"Kotler E, Shani O, Goldfeld G, Lotan-Pompan M, Tarcic O, Gershoni A, Hopf TA, Marks DS, Oren M, Segal E (2018) A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation. Mol Cell 71(1):178-190 e178. https:\/\/doi.org\/10.1016\/j.molcel.2018.06.012","journal-title":"Mol Cell"},{"issue":"3","key":"6771_CR33","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.bpj.2019.12.015","volume":"118","author":"A Garg","year":"2020","unstructured":"Garg A, Hazra JP, Sannigrahi MK, Rakshit S, Sinha S (2020) Variable mutations at the p53-R273 oncogenic hotspot position leads to altered properties. Biophys J 118(3):720\u2013728. https:\/\/doi.org\/10.1016\/j.bpj.2019.12.015","journal-title":"Biophys J"},{"issue":"4","key":"6771_CR34","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ijc.10405","volume":"99","author":"WS Samowitz","year":"2002","unstructured":"Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF, Slattery ML (2002) Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 99(4):597\u2013602. https:\/\/doi.org\/10.1002\/ijc.10405","journal-title":"Int J Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06771-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06771-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06771-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:03:51Z","timestamp":1771398231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06771-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["6771"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06771-1","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was approved by the Institutional Review Board of Peking University Third Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}